Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study ( EROICA study)
Authors' conclusion
Switching to ezetimibe 10 mg/rosuvastatin 2.5 mg achieved substantial LDL-C reductions, high goal attainment, excellent adherence, and good tolerability in Korean T2DM patients with dyslipidaemia.
Study context
- Population
- Korean adults with T2DM and LDL-C ≥70 mg/dL despite ≥12 weeks of moderate or low-intensity statin therapyfull analysis set
- Participants
- 586 adults
- Exposure
- Switch from moderate- or low-intensity statin monotherapy to ezetimibe 10 mg/rosuvastatin 2.5 mg
- Outcome
- Proportion achieving LDL-C <70 mg/dL
- Follow-up
- Week 12
Methodological detailsmulticentre, open-label
- Multicentre
- Open-label
Main finding
As reported in the abstract
LDL-C <70 mg/dL
Ezetimibe 10 mg/rosuvastatin 2.5 mg
62.3%
95% CI 58.4–66.2
Observational data: associations, not effects.
Secondary outcomes
Mean LDL-C change from baseline · Week 12
- Mean LDL-C decreased by 26.0% from 90.9 ± 17.2 to 67.3 ± 19.3 mg/dL
- P < 0.001
Other lipids · Week 12
- Total cholesterol, non-HDL-C and apoB decreased significantly
- all p < 0.001
- HDL-C unchanged
- P = 0.914
- TG unchanged
- P = 0.393
Glycaemic parameters · Week 12
- HbA1c increased by 0.15 ± 0.53%
- P < 0.001
- Fasting glucose increased by 3.6 ± 24.7 mg/dL
- P < 0.001
- HOMA-IR decreased by −0.22 ± 3.09, not significant
- P = 0.085
LDL-C reduction by subgroup
- Greater LDL-C reductions with BMI <23 kg/m², prior low-intensity statin use or pravastatin; smaller with GLP-1 RA or TZD
Adherence
- Mean adherence
- 97.5%
- Adherence ≥80%
- 97.4%
Safety
≥1 adverse event
- Participants with at least one adverse event, mostly mild and not clinically significant
- 9.8%
- 591 participants in safety analysis
Original publication
Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study ( EROICA study). Diabetes Obes Metab. Published 5 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →